While opioids represent a relatively small percentage of the cooperative’s total sales, they account for significant legal and compliance expenses, the distributor said.
“The ever-increasing expenses associated with the legal and regulatory compliance for this segment of drugs are simply not sustainable,” the company wrote in a news release.
The company will continue distributing its other products and said it plans to focus more on generic drugs.
Read the full news release here.
More articles on pharmacy:
CVS to add 600 HealthHUBs, link them to lower Aetna copays
Civica Rx calls on generic drugmakers to donate to its cause
Pfizer, GlaxoSmithKline give timeline for IPO of joint venture
